Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial | Zendy

Jinghao Zhang | Zendy; Xin Zhang | Zendy; Zhenhua Zhou | Zendy; Xiaojun Zhu | Zendy; Chao Zheng | Zendy; Man Li | Zendy; Shu-Gen Jin | Zendy; Dewen Mao | Zendy; Jingdong Xue | Zendy; Wei-Bing Shi | Zendy; Xiaoling Chi | Zendy; Xianbo Wang | Zendy; Xiaodong Li | Zendy; Yong Li | Zendy; Hui Wang | Zendy; Qin Li | Zendy; Da-qiao Zhou | Zendy; Cheng-Bao Wang | Zendy; Changhe Shi | Zendy; Chengzhong Li | Zendy; Jian Wu | Zendy; Xiaoni Kong | Zendy; Xuehua Sun | Zendy; Yueqiu Gao | Zendy

Open Access

Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Author(s) -

Jinghao Zhang,

Xin Zhang,

Zhenhua Zhou,

Xiaojun Zhu,

Chao Zheng,

Man Li,

Shu-Gen Jin,

Dewen Mao,

Jingdong Xue,

Wei-Bing Shi,

Xiaoling Chi,

Xianbo Wang,

Xiaodong Li,

Yong Li,

Hui Wang,

Qin Li,

Da-qiao Zhou,

Cheng-Bao Wang,

Changhe Shi,

Chengzhong Li,

Jian Wu,

Xiaoni Kong,

Xuehua Sun,

Yueqiu Gao

Publication year - 2022

Publication title -

evidence-based complementary and alternative medicine

Language(s) - English

Resource type - Journals

eISSN - 1741-4288

pISSN - 1741-427X

DOI - 10.1155/2022/6097221

Subject(s) - entecavir , medicine , hbsag , hbeag , cccdna , gastroenterology , placebo , hepatitis b virus , chronic hepatitis , clinical endpoint , hepatitis b , randomized controlled trial , immunology , virus , lamivudine , pathology , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research